← All trials
NCT05556720
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2022
- Primary completion
- Feb 28, 2024
- Completion date
- Dec 31, 2025
- First posted
- Sep 27, 2022
- Last posted
- Sep 27, 2022
- Enrollment
- 960
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Monash UniversityLead sponsor
- Monash UniversityCollaborator
- Monash UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.